Arena Capital Advisors’s AEON Biopharma AEON Stock Holding History

Arena Capital Advisors’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-425	Closed	-$308K	–	109
2022 Q4	$308K	Hold	425	–	–	0.17%	57
2022 Q3	$302K	Hold	425	–	–	0.09%	97
2022 Q2	$300K	Sell	425 -425	-50%	-$300K	0.08%	111
2022 Q1	$599K	Sell	850 -2,617	-75%	-$1.84M	0.09%	131
2021 Q4	$2.43M	Hold	3,467	–	–	0.22%	138
2021 Q3	$2.43M	Buy	+3,467	New	+$2.42M	0.19%	150

Other funds holding AEON

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

GCWM

Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Arena Capital Advisors's AEON Position: Q1 2023 in Review

Arena Capital Advisors sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 425 shares — an estimated $308K sold.

Arena Capital Advisors first reported a position in AEON in Q3 2021 and held it in 6 quarters. The position peaked at $2.43M in Q3 2021. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

Arena Capital Advisors reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
Arena Capital Advisors sold 425 AEON Biopharma shares in Q1 2023, an estimated $308K.
Arena Capital Advisors first reported a position in AEON Biopharma in Q3 2021 and held it in 6 quarters.
Arena Capital Advisors's AEON Biopharma position peaked at $2.43M in Q3 2021.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Arena Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.